New Initiative Boosts Early Diagnosis and Treatment of Aortic Stenosis

A new initiative launched by the American Heart Association aims to enhance early diagnosis and treatment options for individuals with aortic stenosis (AS). This heart valve condition, characterized by the narrowing of the aortic valve, restricts blood flow from the heart to the body. If left untreated, it can lead to severe complications, including heart failure and even death. By increasing participation in clinical trials and raising awareness, this initiative seeks to ensure that patients receive timely and innovative care.

The initiative, which is part of the Association’s Target: Aortic Stenosis program, is expected to connect at least 40 hospitals with affiliated heart valve clinics. By leveraging the existing infrastructure, the program aims to engage more individuals with moderate AS in clinical research opportunities. Dr. Sreekanth Vemulapalli, the project’s clinical leader and a volunteer member of the scientific advisory group, emphasizes the urgency of this effort. “Aortic stenosis is a serious condition, yet too often, people go undiagnosed until the disease progresses,” Vemulapalli stated. He holds a position as an associate professor of medicine at Duke University and is involved with the Duke Clinical Research Institute.

The initiative is supported by Kardigan, a health technology company focused on advancing cardiovascular care. Dr. Jay Edelberg, co-founder and chief medical officer at Kardigan, expressed enthusiasm for the project. “Improving access to clinical trials will not only advance innovation but also help more people receive the diagnosis and treatment they need sooner,” Edelberg noted. His organization aims to redefine cardiovascular care by going beyond mere symptom management.

Currently, over 2,200 patients with moderate AS are managed through the Association’s quality improvement network. The new initiative intends to enhance this support by providing professional education, quality improvement tools, and site-level resources to clinicians. This will enable them to better identify and refer individuals eligible for clinical trials.

In addition, a healthcare provider climate survey will explore the barriers to clinical trial enrollment. This research aims to inform strategies that will improve participation in studies related to structural heart disease, ultimately ensuring that more patients benefit from emerging medical therapies.

With this initiative, the American Heart Association is taking significant steps towards changing the landscape of care for individuals affected by aortic stenosis. The focus on early diagnosis and access to clinical trials reflects a commitment to improving health outcomes and enhancing the quality of life for patients dealing with this serious condition.